I-MAK Profile picture
A team of lawyers, scientists, and health experts challenging systemic injustice and advocating for health equity in drug development and access.
May 17, 2023 9 tweets 3 min read
In our new report with @econliberties we examine the most widely-practiced strategies pharma employs to game the patent system to extend exclusivities and keep drug prices high.

🧵 on of those tactics ⬇️

Company: Indivior
Drug: Suboxone
Strategy: Product hopping

(1/9) Graphic features an image o... Suboxone is a prescription oral medication marketed by Indivior that minimizes withdrawal symptoms in patients recovering from opioid addiction. (2/9)
Dec 15, 2021 16 tweets 9 min read
🧵 (1/16): Our key takeaways from the House Oversight Committee’s final report concluding its three-year investigation into the pharmaceutical industry’s anti-competitive pricing and business tactics. .@RepMaloney introduces the report with a letter to Committee Members. In it, she reviews what their nearly 3-year investigation revealed:

“Drug companies have raised prices relentlessly for decades while manipulating the patent system and other laws”
May 16, 2021 8 tweets 2 min read
Right now, the list price for a year of treatment with Humira is $77k in the U.S. With the availability of biosimilars, the estimated annual price in the EU is $3.5k.

That’s a whopping 22x price difference.

A 🧵 on why the prices for the exact same drug are so different. AbbVie released Humira in 2002 as an anti-inflammatory treatment.

It raised the price steadily in both the EU & US until 2018, when Humira’s patent protection in Europe ended & biosimilar competitors could enter the market.

The result: W/in 4 months, Humira’s price dropped 70%.
May 14, 2021 6 tweets 4 min read
Need to prepare for next week’s drug pricing hearing with AbbVie? Here’s a thread of four useful resources to read and listen to. ⤵️ “Protect at all costs: how the maker of the world’s bestselling drug keeps prices sky-high”

By @the_sy_guy - @FortuneMagazine
fortune.com/longform/abbvi…